Physician profile
Sumithira Vasu
NPI 1710159744
$31,388.21
in general payments reported to CMS, 2019-2025
14 companies · $8,397 in 2025
The $8,397 reported for 2025 was more than what 76% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,094 · 2020: $16K · 2021: $1,250 · 2022: $1,410 · 2023: $238 · 2024: $1,249 · 2025: $8,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,520 · Travel and Lodging: $2,465 · Food and Beverage: $1,495 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,520.00 |
| Travel and Lodging | $2,464.94 |
| Food and Beverage | $1,495.02 |
| Education | $403.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $18,844.40 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $6,427.26 | 2025 | |
| National Marrow Donor Program | $3,408.84 | 2023-2025 | |
| Boehringer Ingelheim International Gmbh | $1,410.17 | 2022 | |
| Alexion Pharmaceuticals, INC. | $1,250.00 | 2021 | |
| Iovance Biotherapeutics, INC. | $47.54 | 2024 | Amtagvi |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumithira Vasu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.